![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A 12-Week Interferon-Free Regimen of ABT-450/r + ABT-333 + Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naïve HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders
|
|
|
Reported by Jules Levin
47th Annual Meeting of the European Association for the Study of the Liver · Barcelona, Spain · April 18-22, 2012
Fred Poordad1, Eric Lawitz2, Kris V. Kowdley3, Gregory T. Everson4, Bradley Freilich5, Daniel Cohen6, Sara Siggelkow6, Michele Heckaman6, Rajeev Menon6, Tami Pilot-Matias6, Thomas Podsadecki6, Barry Bernstein6
1: Cedars-Sinai Medical Center, Los Angeles, CA, 2: Alamo Medical Research, San Antonio, TX, 3: Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, 4: University of Colorado Denver and University of Colorado Hospital, Aurora, CO, 5: Kansas City Gastroenterology & Hepatology, Kansas City, MO, 6: Abbott, Abbott Park, IL
![EASL1.gif](../images/042312/042312-1/EASL1.gif)
![EASL2.gif](../images/042312/042312-1/EASL2.gif)
![EASL3.gif](../images/042312/042312-1/EASL3.gif)
![EASL4.gif](../images/042312/042312-1/EASL4.gif)
![EASL5.gif](../images/042312/042312-1/EASL5.gif)
![EASL6.gif](../images/042312/042312-1/EASL6.gif)
![EASL7.gif](../images/042312/042312-1/EASL7.gif)
![EASL8.gif](../images/042312/042312-1/EASL8.gif)
![EASL9.gif](../images/042312/042312-1/EASL9.gif)
![EASL10.gif](../images/042312/042312-1/EASL10.gif)
![EASL11.gif](../images/042312/042312-1/EASL11.gif)
![EASL12.gif](../images/042312/042312-1/EASL12.gif)
![EASL13.gif](../images/042312/042312-1/EASL13.gif)
![EASL14.gif](../images/042312/042312-1/EASL14.gif)
![EASL15.gif](../images/042312/042312-1/EASL15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|